The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Implementation of Formalin-Fixed, Paraffin-Embedded Cell Line Pellets as High-Quality Process Controls in Quality Assessment Programs for KRAS Mutation Analysis

På svenska

Author

  • Jeroen R. Dijkstra
  • Frank J. M. Opdam
  • Jerry Boonyaratanakornkit
  • E. Ralf Schoenbrunner
  • Mona Shahbazian
  • Anders Edsjö
  • Gerald Hoefler
  • Andreas Jung
  • Athanassios Kotsinas
  • Vassilis G. Gorgoulis
  • Fernando Lopez-Rios
  • Karin de Stricker
  • Etienne Rouleau
  • Bart Biesmans
  • J. Han J. M. van Krieken
Show all

Summary, in English

In recent years, the mutational status of the KRAS oncogene has become incorporated into standard medical care as a predictive marker for therapeutic decisions related to patients with metastasized colorectal cancer. This is necessary, because these patients benefit from epidermal growth factor receptor (EGFR)-targeted therapy with increased progression-free survival only if the tumor does not carry a mutation in KRAS. Many different analytical platforms, both those commercially available and those developed in house, have been used within pathology laboratories to assess KRAS mutational status. For a testing laboratory to become accredited to perform such tests, it is essential that they perform reliability testing, but it has not previously been possible to perform this kind of testing on the complete workflow on a large scale without compromising reproducibility or the mimicry of the control sample. We assessed a novel synthetic control for formalin-fixed, paraffin-embedded (FFPE) tumor samples in a blind study conducted within nine laboratories across Europe. We show that FFPE material can, at least in part, mimic clinical samples and we demonstrate this control to be a valuable tool in the assessment of platforms used In testing for KRAS mutational status. (J Mal Diagn 2012; 14:187-191; DOI: 10.1016/j.jmoldx.2012.01.002).

Department/s

Publishing year

2012

Language

English

Pages

187-191

Publication/Series

The Journal Of Molecular Diagnostics

Volume

14

Issue

3

Document type

Journal article

Publisher

Elsevier

Topic

  • Cancer and Oncology

Status

Published

ISBN/ISSN/Other

  • ISSN: 1525-1578